Therefore, from the overall summary (Table 1) of this section, we may surmise that downregulation of NRF2 in aggressive PCa (PC3 and DU145) and upregulation of NRF2 in normal cells surrounding the tumor and early stage PCa cells (LNCaP cells, TRAMPC1 cells and TRAMPC mouse models) may be advantageous against PCa growth. The gene discussed is NFE2L2; the disease is neoplasm.